United States (National)

Paul Weiss Rifkind Wharton & Garrison remains a formidable presence in the national litigation market, with recognized strength across securities litigation, antitrust, regulatory matters, investigations and complex commercial disputes. While market observers continue to track the firm's evolution, peer and client feedback alike confirm that Paul Weiss remains among the leading firms handling business-critical litigation. Several securities litigators place the firm among the premier names in the field. Clients are similarly positive, praising the firm for "thoughtful, thorough and pragmatic advice" that is both strategic and commercially focused. One client highlights the team's proactive approach and ability to anticipate concerns before they become urgent, describing the firm as "excellent communicators" who consistently provide substantial value.

The firm's securities litigation practice continues to command particular respect in the market. New York's Audra Soloway receives repeated praise from peers, with competitors across the securities bar identifying her as one of the most highly regarded practitioners in the space. Her acclaim reflects the broader strength of Paul Weiss's shareholder and securities disputes platform. Soloway was part of the firm's securities litigation team that recently secured dismissal with prejudice of a putative securities class action against Regeneron and four of its executives concerning alleged misrepresentations surrounding sales of the retinal disease drugs Eylea and Eylea HD. Beyond securities matters, lawyers who have worked with or against the firm consistently emphasize the sophistication of its strategic counsel and the depth of its government-facing expertise. One commentator describes the team as possessing "deep government expertise" that is invaluable in regulatory and national security matters, while another points to its "deep bench of expertise" and highly strategic approach to complex disputes.

The firm's commercial litigation capabilities are equally noteworthy. Jaren Janghorbani, chair of the firm's complex commercial litigation practice and a member of the executive committee, exemplifies the breadth of the firm's disputes platform. Janghorbani recently helped secure a significant victory for Metsera in Delaware litigation arising from Pfizer's proposed $10 billion acquisition of the clinical-stage biopharmaceutical company. The Paul Weiss team successfully defeated an effort to block a competing bid from Novo Nordisk, preserving Metsera's ability to evaluate an alternative transaction and maximize shareholder value. The firm's depth in deal-related disputes is further illustrated by its representation of Edwards Lifesciences in a $140 million earnout dispute stemming from its acquisition of Harpoon Medical.

Paul Weiss also continues to distinguish itself in antitrust litigation. Bill Michael, who leads the firm's antitrust litigation practice, played a leading role in securing a complete defense victory for Intuitive Surgical in a high-stakes antitrust trial involving allegations that the company unlawfully tied the sale and servicing of its da Vinci surgical robotics systems to the purchase of related instruments. Michael is also among the lawyers representing Regeneron Pharmaceuticals in an antitrust action against Novartis and Vetter Pharma, further illustrating the firm's work on complex competition disputes at the intersection of antitrust and intellectual property law.

The firm's national platform is further strengthened by highly regarded practitioners across multiple offices. In California, Melinda Haag continues to earn recognition from peers, one of whom simply describes her as "excellent." Meanwhile, the recent arrival of Adam Hoeflich has also drawn favorable market attention, with one peer describing him as an exceptionally established practitioner. Together, these practitioners reinforce a bench that remains deep and versatile across securities, antitrust, regulatory and complex commercial disputes.


Updated October 2026